Ministry of Finance’s Nagayasu Discusses Public Fund Utilization: “Cost-Effectiveness is Absolutely Essential” for Pharmaceuticals; Immediate Listing Post

News Highlights

Mr. Nagayasu, a chief official at the Ministry of Finance, emphasized that “cost-effectiveness is absolutely essential” for pharmaceuticals utilizing public funds. He stated that immediate listing after regulatory approval is “privileged,” and argued for the necessity of stricter cost-effectiveness evaluations from the perspective of controlling healthcare costs. This raises questions about the balance between incentivizing new drug development and maintaining universal health insurance, and could potentially impact future drug pricing and reimbursement schemes.

Perspective from M&A Medical Editorial Department

The remarks by Mr. Nagayasu from the Ministry of Finance contain important implications for the management of medical institutions, particularly when considering the introduction of new drugs. As concerns grow over the increase in healthcare costs funded by public resources, an era where the “cost-effectiveness” of pharmaceuticals is rigorously scrutinized has arrived. The background to immediate listing post-regulatory approval being described as “privileged” lies in the strained state of public health insurance finances. This issue extends beyond mere drug price negotiations and will likely influence the criteria for selecting pharmaceuticals introduced by medical institutions. For instance, even for expensive new drugs, if their cost-effectiveness is unclear, their inclusion in insurance coverage may be delayed or their application may be limited. Medical institutions are increasingly required not only to pursue the latest treatments but also to calmly evaluate their economic rationality, i.e., cost-effectiveness, and incorporate it into their management strategies. This also means that when considering M&A, the cost-effectiveness analysis of the acquired medical institution’s pharmaceutical portfolio will become even more crucial during due diligence.

Key Discussion Points from This News

• The Ministry of Finance has explicitly stated the absolute necessity of “cost-effectiveness” in the utilization of public funds for pharmaceuticals.
• The view that immediate listing post-regulatory approval is “privileged” suggests an impact on future drug pricing and reimbursement processes.
• From the perspective of controlling healthcare costs, cost-effectiveness evaluation at the time of new drug introduction will be a key factor in management decisions.
• Medical institutions are compelled to incorporate a balance between introducing the latest treatments and economic rationality into their management strategies.

Practical Questions Arising from This News

• What specific evaluation criteria for “cost-effectiveness” will be established in the future?
• If immediate listing post-regulatory approval becomes difficult, what alternative measures should medical institutions take?
• What points should medical institutions introducing high-priced new drugs pay particular attention to when considering M&A?

If You Feel “Should I Consult?”

Have you objectively evaluated the cost-effectiveness of the pharmaceuticals your institution introduces? Have you developed a management strategy that considers the risks of future drug price revisions and changes in insurance reimbursement? If you have concerns about the criteria for introducing new drugs or building a future healthcare delivery system, consulting with an M&A specialist can be effective. We will accurately assess your institution’s current situation and work with you to consider the optimal options for the future.

M&A Medical (CentralMedience Inc.) supports the business succession of medical corporations, hospitals, and clinics with a complete success fee system as an M&A support institution certified by the Small and Medium Enterprise Agency. We handle consultations with strict confidentiality. Free consultation here